Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018 financials, which saw sales growth of 8% and 14%, respectively. That's especially impressive given the current...read more
Avedro, which sells ophthalmic drug device systems used in treating corneal disorders, raised $70 million by offering 5 million shares at $14, the low end of the $14 to $16 range. At pricing, Avedro commands a fully diluted market capitalization of $270 million and an enterprise value of $211 million. Avedro plans to list on the Nasdaq under the symbol AVDR. BofA Merrill Lynch and...read more
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six combined. These others are mostly small healthcare IPOs: ...read more
Avedro, which sells ophthalmic medical systems used in treating corneal disorders, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Avedro would command a fully diluted market value of $290 million. Avedro was founded in 2002...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
US IPO Weekly Recap: Blue jeans are back as Levi's preps March IPO
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018 financials, which saw sales growth of 8% and 14%, respectively. That's especially impressive given the current...read more
Avedro prices IPO at $14, the low end of the range
Avedro, which sells ophthalmic drug device systems used in treating corneal disorders, raised $70 million by offering 5 million shares at $14, the low end of the $14 to $16 range. At pricing, Avedro commands a fully diluted market capitalization of $270 million and an enterprise value of $211 million. Avedro plans to list on the Nasdaq under the symbol AVDR. BofA Merrill Lynch and...read more
US IPO Week Ahead: On track for 7 IPOs, led by Virgin Trains USA
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six combined. These others are mostly small healthcare IPOs: ...read more
Ophthalmic medical device maker Avedro sets terms for $75 million IPO
Avedro, which sells ophthalmic medical systems used in treating corneal disorders, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Avedro would command a fully diluted market value of $290 million. Avedro was founded in 2002...read more